Business Context and Reporting Period
This Form 8-K reports on the results of the adjourned 2021 Special Meeting of Stockholders held by Seneca Biopharma, Inc. (trading symbol: SNCA) on April 9, 2021. The meeting was conducted virtually to vote on proposals related to a proposed merger with Leading BioSciences (LBS) and the subsequent rebranding to Palisade Bio, Inc.
Key Financial Metrics
This filing is a current report regarding corporate governance and stockholder votes; it does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data.
Material Changes and Voting Results
The filing details the preliminary voting results for six proposals. As of the Record Date (February 9, 2021), 17,295,703 shares were outstanding, with 9,489,421 shares represented at the meeting.
- Proposal 1 (Reverse Stock Split): Failed to pass at the time of the meeting. This proposal required approval of a reverse stock split (ratio between 1-for-5 and 1-for-12) to effect the merger. Preliminary votes were 8,135,793 For, 1,316,250 Against, and 37,378 Abstentions. The meeting was adjourned to April 23, 2021, to solicit additional votes.
- Proposal 2 (Merger and Change of Control): Approved. Preliminary votes were 4,946,367 For, 645,337 Against, and 88,291 Abstentions.
- Proposal 3 (2021 Equity Incentive Plan): Approved. Preliminary votes were 3,375,812 For, 2,051,763 Against, and 252,420 Abstentions.
- Proposal 4 (2021 Employee Stock Purchase Plan): Approved. Preliminary votes were 3,580,788 For, 1,906,851 Against, and 192,356 Abstentions.
- Proposal 5 (Executive Compensation Advisory Vote): Approved. Preliminary votes were 4,552,021 For, 853,452 Against, and 274,522 Abstentions.
- Proposal 6 (Adjournment): Approved. Preliminary votes were 7,872,512 For, 1,444,146 Against, and 172,763 Abstentions.
Guidance, Outlook, and Risks
Outlook and Next Steps: The Special Meeting was adjourned until April 23, 2021, specifically to allow Seneca to solicit additional votes for Proposal 1 (the reverse stock split). During the adjournment period, the company will continue to accept votes on Proposal 1 only. The reconvened meeting will be held virtually.
Risks and Contingencies: The primary contingency is the failure to secure sufficient votes for the reverse stock split by the April 23 deadline. Without approval of Proposal 1, the merger with Leading BioSciences and the associated corporate changes cannot proceed as planned. The filing notes that Proposal 1 requires a higher standard to pass than the other proposals.
Investor Verification Checklist
- Verify the final voting results for Proposal 1 (Reverse Stock Split) after the adjourned meeting on April 23, 2021.
- Confirm whether the merger with Leading BioSciences (LBS) proceeds following the stockholder vote.
- Monitor the ticker symbol change from SNCA to the new symbol for Palisade Bio, Inc., pending merger completion.
- Review the specific reverse stock split ratio once mutually agreed upon by the Company and LBS.